Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABR-217620 (naptumomab estafenatox) plus interferon alfa vs interferon alfa in advanced renal cell carcinoma
2006-004956-19Phase 2Completed
- Sponsor
- Active Biotech AB
- Start
- Feb 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of naptumomab estafenatox in renal cell carcinoma (RCC) (2 arms), sponsored by Active Biotech AB. Primary endpoint: Time to death. Started Feb 2007; status: completed.
02
Drugs
naptumomab estafenatox
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2006-004956-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004956-19.